

## Acute Health Division

### Hospital Circular

Human  
Services



Peoplefirst

**Distribution:** Public Hospitals

**Subject:** Highly Specialised Drugs Program - Price change for Disodium Pamidronate

**Purpose:** The purpose of this circular is to advise hospitals involved with the Highly Specialised Drugs Program of a price change for Disodium Pamidronate.

---

We have had recent advice from the Commonwealth regarding an error in the advised price for Disodium Pamidronate.

As from 1 November 1997, the reimbursable price for Disodium Pamidronate under the Highly Specialised Drugs Program will be as follows:

**DISODIUM PAMIDRONATE (Aredia)**

Injection set, powder for IV infusion, 90mg/10mL solvent Pack size 1, Price \$387.03

*Indication:* Predominantly lytic bone disease due to advanced multiple myeloma.

**EFFECTIVE SUBSIDY DATE: 1 November 1997**

Please find attached the relevant pages to revise Appendices 3 and 8 of the Commonwealth/State Highly Specialised Drugs Program Guidelines, August 1997. You should update your guidelines with the attached pages.

Also note, this circular can also be found on HosNet.

**DR C W BROOK**  
DIRECTOR  
ACUTE HEALTH

---

Date

Publication No.

Originating Unit

Series Title

21 October 1997

17/1997

Central Office

## Appendix 3: Agreed Prices

Drug & dose form information	Pack size	Agreed Price	
		1997/98	
		Per Pack	Per Item
<b>Apomorphine</b>			
Injection, 10mg in 1 ml amp	5	\$28.00	\$5.6000
<b>Clarithromycin</b>			
Tablet, 250mg	100	\$199.80	\$1.9980
Tablet, 500mg	100	\$389.60	\$3.8960
<b>Clozapine</b>			
Tablet, 25mg	100	\$72.00	\$0.7200
Tablet, 100mg	100	\$270.00	\$2.7000
<b>Neoral (Cyclosporin)</b>			
Capsule, 25mg,	50	\$80.02	\$1.6004
Capsule, 50mg	50	\$160.00	\$3.2000
Capsule, 100mg	50	\$320.00	\$6.4000
Oral Solution, 100mg/mL, 50mL	1	\$336.85	\$336.8500
<b>Cyclosporin (Sandimmun)</b>			
Ampoules, 50mg/ml	10	\$54.10	\$5.4100
Ampoules, 250mg/5ml	10	\$257.95	\$25.7950
<b>Desferrioxamine (Desferal) and Generic</b>			
Powder, 500mg	10	\$100.00	\$10.0000
<b>Didanosine (DDI) (Videx)</b>			
Powder, 2g (paediatric soln)	1	\$52.77	\$52.7700
Tablet, 25mg	60	\$39.58	\$0.6597
Tablet, 100mg	60	\$158.31	\$2.6385
<b>Disodium Pamidronate (Aredia)</b> Available from 1 November 1997			
Inj. set. powder for IV infusion, 90mg/10mL sol	1	\$387.03	\$387.0300
<b>Dornase Alpha (Pulmozyme)</b>			
Sol for inhalation, 2.5mg/2.5ml	30	\$1,125.00	\$37.5000
<b>Erythropoietin</b>			
Vials, 2,000u	6	\$272.00	\$45.3333
Vials, 4,000u	6	\$447.00	\$74.5000
Vials, 10,000u	6	\$1,037.00	\$172.8333
Sol for inj., 1,000u/0.5ml	6	\$147.00	\$24.5000
Sol for inj., 2,000u/0.5ml	6	\$272.00	\$45.3333
Sol for inj., 3,000u/0.3ml	6	\$351.00	\$58.5000
Sol for inj., 4,000u/0.4ml	6	\$447.00	\$74.5000
Sol for inj., 10,000u/1ml	6	\$1,037.00	\$172.8333

# HIGHLY SPECIALISED DRUGS PROGRAM

Claim Form  
For the Period from                      to

## Disodium Pamidronate (Aredia)

<b>Patient Information</b>	<b>Number of Patients*</b>
Community Patients	

<b>Dispensing Information</b>			
<b>Dosage Form, Strength</b>	<b>Number of Items Dispensed</b>	<b>Cost per Item</b>	<b>Expenditure</b>
Inj. set, powder for IV infusion, 90mg/10mL solvent		\$387.0300	
	<b>Total Expenditure</b>		

I certify that the Disodium Pamidronate claimed was dispensed to patients who met the Highly Specialised Drugs Program's criteria, including PBAC indications and that the amount claimed is correct.

AUTHORISING SIGNATURE:

DATE:

NAME OF SIGNATORY:

CONTACT PHONE NO:

POSITION:

\*Number of patients represents total number of individual patients who received supply of highly specialised drugs in quarter, NOT number of occasions of dispensing.